Despite great progress on case–control polygenic prediction, an unmet need remains for a method that genetically distinguishes clinically related disorders (e.g., schizophrenia (SCZ) versus bipolar disorder (BIP) versus major depressive disorder (MDD) versus controls). We introduce differential diagnosis–polygenic risk...
W. Peyrot, G. Panagiotaropoulou, L. O. Olde Loohuis et al.· Nature Genetics· 0 citations
Introduction Limitations of current classifications of schizophrenia, schizoaffective disorder, and bipolar disorder are evident from their overlapping symptoms, aetiologies, treatments, and outcomes, and present a barrier to novel treatment discovery. Alternative conceptualisations are needed to address nosological va...
Charlotte A. Dennison, S. Legge, A. Cardno et al.· medRxiv· 0 citations
Case-Case GWAS is used to identify common genetic variants differentially associated with schizophrenia and bipolar disorder, analysing 67,390 schizophrenia cases and 41,917 bipolar disorder cases and demonstrating that genuine divergent genetic effects exist beyond the substantial shared liability.
I. Willcocks, A. Richards, S. Legge et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
